Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "fc points apple pay Buyfc26coins.com is FC 26 coins official site..1Z6B"

Looking for quality documents?
external link icon
Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
WALTHAM, Mass., May 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr. Hunt was most recently President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. At Life Technologies, Mr. Hunt played a key role in the development and growth of the company's bioprocessing business, where he focused on expanding the upstream Gibco® cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt is an accomplished life sciences industry veteran who will oversee commercial and manufacturing operations for Repligen. "We welcome Tony to the Repligen management team, where his industry knowledge and understanding of bioproduction market drivers will help guide the
external link icon
Repligen to Present at the 2013 Stephens Fall Investment Conference
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 at 10:00 a.m. EST. The annual conference will take place November 12-13, 2013 at the New York Palace Hotel in New York. The Repligen presentation will not be webcast, however the slide presentation will be available on the Company's website at www.repligen.com ; see Events & Presentations under Investor Relations. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to
external link icon
Repligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 3:50 p.m. EDT. The annual conference will take place September 11-12 at the Four Seasons Hotel in Boston. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading
external link icon
Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. EDT. The conference will take place June 3-6 at the Grand Hyatt New York. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a
external link icon
Repligen CEO to Present at Upcoming Investor Conferences
- Stephens Fall Investment Conference & Piper Jaffray Healthcare Conference - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at two investor conferences in November. Dr. Herlihy will first participate in the Stephens Fall Investment Conference on November 14, and will later present at the Piper Jaffray 24 th Annual Healthcare Conference on November 27. Both conferences will take place at The New York Palace Hotel. At each, Dr. Herlihy will provide a corporate update and address questions from the audience. Repligen’s presentation at the Piper Jaffray Annual Healthcare Conference will be webcast and made available live through the Investors section of Company’s website at www.repligen.com . This presentation is currently scheduled to begin on Tuesday, November 27 at 8:50 a.m. EST. To access the live webcast, please log on approximately 15 minutes prior to the scheduled start time. The
corporate icon
N-1 Perfusion
A form of seed train intensification, N-1 perfusion refers to the intensification of cell growth in the seed train step (N-1) before the production bioreactor (N), achieving a more rapid and robust process while maintaining an existing Fed-Batch based production scheme.
external link icon
Repligen to Report Third Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of Company’s website. About
external link icon
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors. Craig-Hallum’s 22 nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series of one-on-one meetings with investors. A live webcast of the RBC conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen
external link icon
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658
external link icon
Repligen Corporation to Present at Upcoming June Investor Conferences
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences.
William Blair’s 44 th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies’ Global Healthcare Conference being held in New York from June 5 – 6, 2024. Olivier Loeillot, President and Chief Commercial Officer and Jason K. Garland, Chief Financial Officer, are scheduled to participate in an analyst-led discussion on June 6 at 11:30 a.m. ET. A live webcast of the conference presentations will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support